A Phase 2 interventional study of Pemigatinib in MPN (Myeloproliferative Neoplasms), sponsored by Incyte Corporation. Completed at 33 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Myeloproliferative Disorders by Incyte Corporation — 3 open to participants now, 7 under way, none of them phase 3. Myeloproliferative Disorders · Incyte Corporation.
Among the 25 studies in Myeloproliferative Disorders by Incyte Corporation, this one is the 18th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2017, is one of 10 in phase 2, and was the 13th registered.
668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.
Browse Myeloproliferative Disorders studies →3 of the 25 studies in Myeloproliferative Disorders by Incyte Corporation are open now, in 11 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 2 more countries
Ages 18+
Incyte Corporation · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 88 Myeloproliferative Disorders studies recruiting now, 64 (73%) set no upper age limit and 18 (20%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 3
First in 2008; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is close to the median of 47 across 463 interventional studies indexed under Myeloproliferative Disorders.
Median enrollment 97 across the 23 interventional studies, 2,007 across the 2 observational. Of the 18 that completed or were terminated, 15 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
1 of the studies in Myeloproliferative Disorders by Incyte Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04279847Incyte CorporationSafety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Myeloproliferative Disorders by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligible subjects must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pemigatinib
Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy. Participants will receive either the intermittent dose (as written) or continuous dosing.
Also known as: INCB054828
Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
CR was defined as the presence of all of the following improvements: (1) bone marrow: ≤5% myeloblasts (including monocytic blast equivalent) and no lymphoblasts, with normal maturation of all cell lines, and return to age-adjusted normal cellularity; (2) osteomyelofibrosis absent or equal to "mild reticulin fibrosis" (Grade 1 or less fibrosis); (3) peripheral blood: white blood cells (WBC) ≤10 x 10\^9 cells/Liter (L); hemoglobin (Hgb) ≥11 grams per deciliter (g/dL); platelets ≥100 x 10\^9/L and ≤450 x 10\^9/L; neutrophils ≥1.0 x 10\^9/L; blasts = 0%; neutrophil precursors reduced to ≤2%; monocytes ≤1 x 10\^9/L; eosinophils ≤0.5 x 10\^9/L; (4) extramedullary disease: complete resolution of extramedullary disease present before therapy (e.g., lymphadenopathy), including palpable hepatosplenomegaly. Persistent low-level dysplasia was permitted given subjectivity of assignment of dysplasia. Response criteria by investigator assessment were the same for chronic phase (CP) and blast phase (BP).
Time frame: up to 2513 days (120 21-day treatment cycles)
Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
CR=all of the following improvements: (1) bone marrow: ≤5% myeloblasts (including monocytic blast equivalent) and no lymphoblasts, with normal maturation of all cell lines, and return to age-adjusted normal cellularity; (2) osteomyelofibrosis absent/equal to "mild reticulin fibrosis"; (3) WBC ≤10 x 10\^9 cells/L; Hgb ≥11 g/dL; platelets ≥100 x 10\^9/L, ≤450 x 10\^9/L; neutrophils ≥1.0 x 10\^9/L; blasts=0%; neutrophil precursors reduced to ≤2%; monocytes ≤1 x 10\^9/L; eosinophils ≤0.5 x 10\^9/L; (4) extramedullary disease: complete resolution of extramedullary disease present pre-therapy, including palpable hepatosplenomegaly. Persistent low-level dysplasia was permitted. PR=all of the following improvements: (1) reduction of bone marrow blasts/blast equivalents by 50%, but remaining \>5% of cellularity (except in cases with ≤5% bone marrow blasts at baseline); (2) normalization of peripheral blood indices per CR Criterion 3; (3) extra medullary disease response of CMR/CR or PMR/PR.
Time frame: up to 2513 days (120 21-day treatment cycles)
Percentage of Participants Who Achieved a Complete Cytogenetic Response (CCyR) as Assessed by Local Analysis and Investigator Evaluation
CCyR was defined as 0% 8p11 translocated metaphases as seen on classic karyotyping with minimal of 20 metaphases, or fluorescence in situ hybridization (FISH). Loss of cytogenetic burden of disease (via FISH or classic karyotyping) was required to reach CCyR.
Time frame: up to 2513 days (120 21-day treatment cycles)
Percentage of Participants Who Achieved a Partial Cytogenetic Response (PCyR) as Assessed by Local Analysis and Investigator Evaluation
PCyR was defined as the decrease from baseline of 50% or more 8p11 translocated metaphases as seen on classic karyotyping with minimal of 20 metaphases, or FISH.
Time frame: up to 2513 days (120 21-day treatment cycles)
Percentage of Participants Who Achieved a PCyR as Assessed by CRC Assessment
In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.
Time frame: up to 2513 days (120 21-day treatment cycles)
Duration of Complete Response
Duration of complete response was defined as the time from the first assessment of complete response to the earlier of the date of first worsening assessment after complete response or death due to any cause
Time frame: up to 2513 days (120 21-day treatment cycles)
Duration of Response
Duration of response was defined as the time from the first assessment of complete response or partial response to the earlier of the date of first worsening assessment after response or death due to any cause.
Time frame: up to 2513 days (120 21-day treatment cycles)
Progression-free Survival (PFS)
PFS was defined as the time from the first date of taking study drug until the date of disease progression or until death due to any cause, whichever was earlier. Disease progression was defined as the combination of 2 major criteria, 1 major and 2 minor criteria, or 3 minor criteria from the following lists. Major criteria: (1) increase in blast count; (2) evidence of cytogenetic evolution (re-appearance of a previously present or appearance of a new cytogenetic abnormality, or increase in cytogenetic burden of disease); (3) new or worsening extramedullary disease (worsening splenomegaly or extramedullary disease outside of the spleen). Minor criteria: (1) transfusion dependence; (2) significant loss of maximal response on cytopenias ≥50% decrement from maximum remission/response in granulocytes or platelets; (3) reduction in Hgb by ≥1.5g/dL from best response or from baseline as noted on complete blood count; (4) evidence of clonal evolution (molecular).
Time frame: up to 2513 days (120 21-day treatment cycles)
Overall Survival
Overall survival was defined as as the time from the first day of taking study drug until death due to any cause
Time frame: up to 2513 days (120 21-day treatment cycles)
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug.
Time frame: up to 2543 days
Number of Participants With Any ≥Grade 3 TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
Time frame: up to 2543 days
Percentage of Participants Who Achieved CR as Determined by Central Review Committee (CRC) Assessment
In addition, responses were assessed by CRC based on Myeloid/Lymphoid Neoplasm International Working Group (MLN IWG) response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.
Time frame: up to 2513 days (120 21-day treatment cycles)
Percentage of Participants Who Achieved a Best Overall Response of CR or PR as Determined by CRC Assessment
In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.
Time frame: up to 2513 days (120 21-day treatment cycles)
Percentage of Participants Who Achieved a CCyR as Assessed by CRC Assessment
In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.
Time frame: up to 2513 days (120 21-day treatment cycles)
| Milestone | Pemigatinib 13.5 mg |
|---|---|
| Started | 47 |
| Completed | 0 |
| Not completed | 47 |
| Withdrew: Death | 16 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Sponsor decision | 17 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Moved to commercial supply of investigational drug | 2 |
| Withdrew: Received first dose of chemotherapy for stem cell transplant | 1 |
| Withdrew: Sponsor's decision | 2 |
CR was defined as the presence of all of the following improvements: (1) bone marrow: ≤5% myeloblasts (including monocytic blast equivalent) and no lymphoblasts, with normal maturation of all cell lines, and return to age-adjusted normal cellularity; (2) osteomyelofibrosis absent or equal to "mild reticulin fibrosis" (Grade 1 or less fibrosis); (3) peripheral blood: white blood cells (WBC) ≤10 x 10\^9 cells/Liter (L); hemoglobin (Hgb) ≥11 grams per deciliter (g/dL); platelets ≥100 x 10\^9/L and ≤450 x 10\^9/L; neutrophils ≥1.0 x 10\^9/L; blasts = 0%; neutrophil precursors reduced to ≤2%; monocytes ≤1 x 10\^9/L; eosinophils ≤0.5 x 10\^9/L; (4) extramedullary disease: complete resolution of extramedullary disease present before therapy (e.g., lymphadenopathy), including palpable hepatosplenomegaly. Persistent low-level dysplasia was permitted given subjectivity of assignment of dysplasia. Response criteria by investigator assessment were the same for chronic phase (CP) and blast phase (BP).
| percentage of participants | Pemigatinib 13.5 mg |
|---|---|
| Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement | 68.9 (53.35 to 81.83) |
In addition, responses were assessed by CRC based on Myeloid/Lymphoid Neoplasm International Working Group (MLN IWG) response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.
| percentage of participants | Pemigatinib 13.5 mg |
|---|---|
| Percentage of Participants Who Achieved CR as Determined by Central Review Committee (CRC) Assessment | 68.9 (53.35 to 81.83) |
CR=all of the following improvements: (1) bone marrow: ≤5% myeloblasts (including monocytic blast equivalent) and no lymphoblasts, with normal maturation of all cell lines, and return to age-adjusted normal cellularity; (2) osteomyelofibrosis absent/equal to "mild reticulin fibrosis"; (3) WBC ≤10 x 10\^9 cells/L; Hgb ≥11 g/dL; platelets ≥100 x 10\^9/L, ≤450 x 10\^9/L; neutrophils ≥1.0 x 10\^9/L; blasts=0%; neutrophil precursors reduced to ≤2%; monocytes ≤1 x 10\^9/L; eosinophils ≤0.5 x 10\^9/L; (4) extramedullary disease: complete resolution of extramedullary disease present pre-therapy, including palpable hepatosplenomegaly. Persistent low-level dysplasia was permitted. PR=all of the following improvements: (1) reduction of bone marrow blasts/blast equivalents by 50%, but remaining \>5% of cellularity (except in cases with ≤5% bone marrow blasts at baseline); (2) normalization of peripheral blood indices per CR Criterion 3; (3) extra medullary disease response of CMR/CR or PMR/PR.
| percentage of participants | Pemigatinib 13.5 mg |
|---|---|
| Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement | 77.8 (62.91 to 88.80) |
In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.
| percentage of participants | Pemigatinib 13.5 mg |
|---|---|
| Percentage of Participants Who Achieved a Best Overall Response of CR or PR as Determined by CRC Assessment | 75.6 (60.46 to 87.12) |
CCyR was defined as 0% 8p11 translocated metaphases as seen on classic karyotyping with minimal of 20 metaphases, or fluorescence in situ hybridization (FISH). Loss of cytogenetic burden of disease (via FISH or classic karyotyping) was required to reach CCyR.
| percentage of participants | Pemigatinib 13.5 mg |
|---|---|
| Percentage of Participants Who Achieved a Complete Cytogenetic Response (CCyR) as Assessed by Local Analysis and Investigator Evaluation | 73.3 (58.06 to 85.40) |
In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.
| percentage of participants | Pemigatinib 13.5 mg |
|---|---|
| Percentage of Participants Who Achieved a CCyR as Assessed by CRC Assessment | 73.3 (58.06 to 85.40) |
PCyR was defined as the decrease from baseline of 50% or more 8p11 translocated metaphases as seen on classic karyotyping with minimal of 20 metaphases, or FISH.
| percentage of participants | Pemigatinib 13.5 mg |
|---|---|
| Percentage of Participants Who Achieved a Partial Cytogenetic Response (PCyR) as Assessed by Local Analysis and Investigator Evaluation | 8.9 (2.48 to 21.22) |
In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.
| percentage of participants | Pemigatinib 13.5 mg |
|---|---|
| Percentage of Participants Who Achieved a PCyR as Assessed by CRC Assessment | 15.6 (6.49 to 29.46) |
Duration of complete response was defined as the time from the first assessment of complete response to the earlier of the date of first worsening assessment after complete response or death due to any cause
| months | Pemigatinib 13.5 mg |
|---|---|
| Investigator assessment | 53.29 (12.22 to NA) |
| CRC assessment | NA (27.86 to NA) |
Duration of response was defined as the time from the first assessment of complete response or partial response to the earlier of the date of first worsening assessment after response or death due to any cause.
| months | Pemigatinib 13.5 mg |
|---|---|
| Investigator assessment | 53.29 (15.51 to NA) |
| CRC assessment | NA (27.86 to NA) |
PFS was defined as the time from the first date of taking study drug until the date of disease progression or until death due to any cause, whichever was earlier. Disease progression was defined as the combination of 2 major criteria, 1 major and 2 minor criteria, or 3 minor criteria from the following lists. Major criteria: (1) increase in blast count; (2) evidence of cytogenetic evolution (re-appearance of a previously present or appearance of a new cytogenetic abnormality, or increase in cytogenetic burden of disease); (3) new or worsening extramedullary disease (worsening splenomegaly or extramedullary disease outside of the spleen). Minor criteria: (1) transfusion dependence; (2) significant loss of maximal response on cytopenias ≥50% decrement from maximum remission/response in granulocytes or platelets; (3) reduction in Hgb by ≥1.5g/dL from best response or from baseline as noted on complete blood count; (4) evidence of clonal evolution (molecular).
| months | Pemigatinib 13.5 mg |
|---|---|
| Investigator assessment | 73.89 (54.74 to NA) |
| CRC assessment | 73.89 (29.17 to NA) |
Overall survival was defined as as the time from the first day of taking study drug until death due to any cause
| months | Pemigatinib 13.5 mg |
|---|---|
| Overall Survival | NA (54.74 to NA) |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug.
| Participants | Pemigatinib 13.5 mg |
|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 47 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
| Participants | Pemigatinib 13.5 mg |
|---|---|
| Number of Participants With Any ≥Grade 3 TEAE | 39 |
Collected over up to 2730 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemigatinib 13.5 mg | 16/47 (34%) | 27/47 (57.4%) | 46/47 (97.9%) |
| Event | Pemigatinib 13.5 mg |
|---|---|
| Acute kidney injuryRenal and urinary disorders | 4/47 |
| Angina pectorisCardiac disorders | 2/47 |
| Atrioventricular block completeCardiac disorders | 2/47 |
| Myocardial infarctionCardiac disorders | 2/47 |
| PneumoniaInfections and infestations | 2/47 |
| SyncopeNervous system disorders | 2/47 |
| Urinary tract infectionInfections and infestations | 2/47 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/47 |
| Aortic stenosisVascular disorders | 1/47 |
| Atrial flutterCardiac disorders | 1/47 |
| Event | Pemigatinib 13.5 mg |
|---|---|
| HyperphosphataemiaMetabolism and nutrition disorders | 35/47 |
| DiarrhoeaGastrointestinal disorders | 29/47 |
| AlopeciaSkin and subcutaneous tissue disorders | 26/47 |
| StomatitisGastrointestinal disorders | 21/47 |
| ConstipationGastrointestinal disorders | 20/47 |
| Dry eyeEye disorders | 20/47 |
| Dry mouthGastrointestinal disorders | 19/47 |
| NauseaGastrointestinal disorders | 17/47 |
| Abdominal painGastrointestinal disorders | 16/47 |
| AnaemiaBlood and lymphatic system disorders | 16/47 |
| Age, Continuous(years) | Pemigatinib 13.5 mg |
|---|---|
| Mean | 58.3 ± 13.25 |
| Sex: Female, Male(Participants) | Pemigatinib 13.5 mg |
|---|---|
| Female | 25 |
| Male | 22 |
| Race/Ethnicity, Customized(Participants) | Pemigatinib 13.5 mg |
|---|---|
| White | 30 |
| Black or African American | 4 |
| Asian | 4 |
| Missing | 5 |
| Not Provided | 2 |
| White/Caucasian and American-Indian Alaska Native | 1 |
| African | 1 |
| Race/Ethnicity, Customized(Participants) | Pemigatinib 13.5 mg |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 33 |
| Not Reported | 8 |
| Unknown | 1 |
| Captured as "Other" in Database | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Apr 2017 to primary completion in Oct 2024, 90 months.
Results were first posted in Nov 2025, 1 year after primary completion.
Of 87 phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 111. This study's 90 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemigatinib
Myeloproliferative Disorders →